Full Press Release Details
QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST).
ZLAB
QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Key Takeaway: QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Price reaction · baseline $144.5 (2021-08-31 close) · hit after-hours · clean, no other ZLAB news in the window
day 0 close · peak
+1.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer